In a population-based analysis of 371,032 UK Biobank participants, faster biological aging in males explained a substantial proportion of their higher cardiovascular disease (CVD) risk compared with females, accounting for about 60–68% of the excess risk across major CVD outcomes. Although males and females had similar chronological ages, males consistently […]
A systematic review of 17 randomized trials involving 66,337 adults found that reducing or modifying saturated fat intake offers little or no clinically meaningful benefit over five years for people at low cardiovascular risk, but may lead to important reductions in mortality and major cardiovascular events among those at high […]
Traditional atherosclerotic cardiovascular disease (ASCVD) risk- and symptom-based screening misses nearly half of patients under age 66 who go on to experience their first myocardial infarction (MI), revealing major shortcomings in current preventive strategies. In this US retrospective study of 465 adults presenting with a first type 1 MI, simulation […]
Adding carotid-artery stenting—but not carotid endarterectomy—to intensive medical management reduced the risk of stroke or death in patients with high-grade asymptomatic carotid stenosis. In two parallel, observer-blinded trials including more than 2,400 participants with ≥70% stenosis, the 4-year incidence of the primary composite outcome (any stroke or death from randomization […]
Low-dose colchicine reduces myocardial infarction and stroke in people with cardiovascular disease (CVD) without increasing serious adverse events, although it raises the risk of mild gastrointestinal symptoms and shows no clear effect on mortality or revascularization. In an updated Cochrane review of 12 randomized controlled trials including 22,983 participants followed […]
Endotyping-informed therapy guided by adenosine stress cardiovascular MRI revised diagnoses in over half of patients with chest pain and unobstructed coronary arteries and significantly improved angina and quality of life at 12 months. In this prospective, multicenter, randomized controlled trial of 250 patients (mean age 63.3 years; 50.4% female) in […]
In patients with ST-segment elevation myocardial infarction (STEMI), early subcutaneous administration of zalunfiban significantly improved coronary artery patency and reduced the risk of adverse 30-day clinical outcomes without increasing severe bleeding. In an international, double-blind, placebo-controlled trial of 2,467 patients randomly assigned to receive zalunfiban (0.11 mg/kg or 0.13 mg/kg) […]
Clonal hematopoiesis of indeterminate potential (CHIP), particularly non-DNMT3A CHIP subtypes, is an independent risk factor for incident heart failure (HF) and may represent a novel therapeutic target. In a UK Biobank cohort of 417,616 adults (mean age, 56.1 years; 56.2% women) without prior HF or major comorbidities, 7,183 participants (1.7%) […]
Daily supplementation with n−3 polyunsaturated fatty acids (fish oil) significantly reduced the risk of serious cardiovascular events in patients receiving maintenance hemodialysis. In a double-blind, randomized, placebo-controlled trial across 26 sites in Canada and Australia, 1,228 adults on hemodialysis were assigned to receive either 4 g of fish oil daily […]
Intracoronary infusion of Wharton’s jelly–derived mesenchymal stem cells after acute myocardial infarction (AMI) significantly reduced the risk of developing heart failure (HF) and related adverse cardiovascular events, suggesting its potential as a valuable adjunctive therapy. In a Iranian phase 3 randomized clinical trial involving 420 patients with a first ST-segment […]